Obviously, treatment can decelerate the progression. .. Advanced liver damage in hepatitis C patients grossly underestimated and underdiagnosed The amount of hepatitis C patients experiencing advanced liver damage may be grossly underestimated and underdiagnosed, relating to a scholarly research led by researchers at Henry Ford Wellness Program and the U.S. Centers for Disease Control and Prevention. The findings were the consequence of a study of nearly 10,000 patients experiencing hepatitis C, and could have a significant effect on patient treatment and healthcare plan regarding the persistent disease. Knowledge of the prevalence of liver harm will help decision making regarding screening for the consequences of hepatitis C, when to start out anti-viral therapy, and the necessity for follow-up counseling, says Stuart Gordon, M.D., lead Director and researcher of Hepatology at Henry Ford Hospital.The American Academy of Orthopaedic Surgeons appreciates this comprehensive and well-considered consider the concerns surrounding the use of these implants. The FDA’s conversation also keeps each of the important stakeholders at heart: patients, potential patients, orthopaedic surgeons and other doctors. With the patient’s basic safety, health, and quality of life in mind always, the people of the AAOS will work with device makers and agencies like the FDA to share knowledge and connect any potential worries. ‘The FDA is somebody in patient safety and education. We are working together to investigate and report these problems and can continue to talk to our 36,000 users, the medical community and the public,’ mentioned AAOS President John J.